Compare Five9 Inc (FIVN) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five9 Inc vs Cassava Sciences Inc — how do they compare? Five9 Inc trades at $25.29 (market cap $1.90B), while Cassava Sciences Inc trades at $1.07 (market cap $53.14M). The key difference: Five9 Inc is far larger — about 35.8× Cassava Sciences Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FIVN | FLNA | |
|---|---|---|
Market Cap | $1.90B | $53.14M |
Sector | Technology | Health |
52-Week High | $29.16 | $4.64 |
52-Week Low | $13.61 | $1.09 |
Enterprise Value | $1.98B | -$33.43M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five9 (FIVN) trades at $25.05, down 2.07% on the day, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals, with revenue growing from $779M in 2022 to $1.15B in 2025 and turning profitable with net income of $39.42M. Recent news highlights AI product launches and workplace awards, while legal scrutiny on insider conduct persists.
The stock presents a positive outlook with strong analyst support (61% buy ratings) and a consensus price target of $27.00, offering ~8% upside. Key risks include negative net cash flow, high debt levels, and ongoing legal investigations into insider fiduciary duties that could pressure sentiment.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
